DasiglucagonGlucagon analogue
Dasiglucagon is an analogue of glucagon developed for severe hypoglycaemia. Its purpose is to raise dangerously low blood glucose when a person cannot reliably treat the episode themselves.
What is Dasiglucagon?
Dasiglucagon is a modified glucagon medicine developed for severe hypoglycaemia: dangerously low blood glucose that may leave someone unable to treat themselves. Its stability in solution allows ready-to-use rescue products. 1 2
How it works
It activates glucagon receptors in the liver, promoting the release of stored glucose into the blood. The response depends partly on available liver glycogen. 2
Effects studied
What does the evidence show?
The archive includes a controlled glucose-recovery study and US product information. Local availability, eligible ages and device instructions need a current product-specific check.
What glucagon signalling does
Glucagon acts on the liver to increase the release of glucose into the bloodstream. Dasiglucagon follows that biological route while using a modified peptide designed for stability in solution. That stability is relevant to ready-to-use rescue presentations, where preparation steps can matter during an emergency.
How the research question was tested
Clinical research can create controlled conditions in which blood glucose is lowered and then measure recovery after treatment. This helps compare a medicine with a control, but it does not capture every real-world emergency. Illness, prolonged fasting, available liver glycogen and the circumstances of administration may change the response. 1
The device is part of the treatment
An effective molecule is only useful in an emergency if the right product is available and someone knows how it is intended to be used. Current instructions, storage and caregiver preparation belong to the specific device. A research protocol cannot replace those product instructions.
Adverse effects and product restrictions
Nausea and vomiting are relevant adverse effects, particularly when someone is already unwell. Certain conditions, including insulinoma and pheochromocytoma, require special attention in product information. Severe hypoglycaemia still needs an emergency response and follow-up to understand why it happened, even when a rescue medicine is available. 2
Safety & status
Nausea and vomiting can occur. Product restrictions include particular endocrine tumours such as insulinoma and pheochromocytoma. Rescue treatment still requires the emergency response and follow-up described in the product instructions. 2
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Is it a daily glucose-control medicine?
No. Its role is rescue from severe low glucose, rather than routine treatment of high glucose. 2
Why might the response vary?
Glucagon relies on the liver’s glucose stores. Prolonged fasting or illness can affect those stores and the response. 2
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Dasiglucagon: paper 10.2337/dc20-2995 Research reference · Retained archive reference; not independently checked for this draft.
- Dasiglucagon: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.